Signals Inbox·August 27, 2026·Biopharma

Has Revolution Medecine's cured pancreatic cancer?

No, Revolution Medicines has not cured pancreatic cancer. But daraxonrasib has already crossed a much more meaningful threshold: it has roughly doubled median survival versus chemotherapy in previously treated metastatic disease, earned FDA approval, and is now being tested in the post-surgery setting where a genuine cure signal could eventually emerge.

Q1What did Revolution Medicines actually get approved for?

Revolution Medicines has now won FDA approval for daraxonrasib in metastatic pancreatic adenocarcinoma, but the approval is for treating advanced cancer rather than curing it.

Rasonque, the brand name for daraxonrasib, can currently be used in adults with metastatic pancreatic adenocarcinoma who have already received at least one systemic treatment, as well as some patients who cannot receive multi-drug systemic therapy.

The scope is important. Pancreatic adenocarcinoma accounts for roughly 90% to 95% of pancreatic cancers, so this is relevant to the main form of the disease rather than a tiny molecular subgroup.

The evidence behind the approval is also unusually solid. RASolute 302 enrolled 500 patients and randomly assigned them to daraxonrasib or standard chemotherapy. The FDA found significant improvements in overall survival, progression-free survival and tumor response.

We are well beyond the stage of calling daraxonrasib an interesting experimental drug. It is now an approved treatment with randomized Phase 3 evidence. The word "cure," though, sets a much higher bar.

Q2Did Revolution Medicines really double survival with daraxonrasib?

Daraxonrasib roughly doubled median survival versus chemotherapy in previously treated metastatic pancreatic cancer, which is an unusually large improvement for this disease.

In RASolute 302, median overall survival reached 13.2 months with daraxonrasib compared with 6.7 months with standard chemotherapy. Median progression-free survival went from 3.6 months to 7.2 months.

The FDA calculated a 0.40 hazard ratio for overall survival. Put more simply, patients receiving daraxonrasib had about a 60% lower risk of death during the observed period than patients in the chemotherapy group.

Tumor responses backed up the survival result. The FDA reported an objective response rate of 30% with daraxonrasib versus 11% with chemotherapy.

That consistency makes RASolute 302 hard to dismiss. Patients were more likely to have their tumors shrink, stayed without progression for considerably longer, and lived longer overall. We rarely get all three measures moving this strongly in the same direction in second-line pancreatic cancer.

RASolute 302 pivotal results

Q3How big a breakthrough is daraxonrasib for pancreatic cancer?

Daraxonrasib currently looks like one of the biggest treatment advances in metastatic pancreatic cancer in years, especially because the strongest evidence comes from patients whose cancer had already progressed after treatment.

The easiest way to see the scale is to compare it with earlier milestones. The original FOLFIRINOX trial moved median survival in first-line metastatic pancreatic cancer from 6.8 months with gemcitabine to 11.1 months. NAPOLI 3 later reported 11.1 months with NALIRIFOX versus 9.2 months with gemcitabine plus nab-paclitaxel.

Those trials cannot be compared head-to-head with RASolute 302 because they enrolled different populations. Still, the order of magnitude tells us something. Daraxonrasib produced 13.2 months of median survival after patients had already gone through one line of treatment.

The earlier Phase 1/2 program also held up unusually well with longer follow-up. In a published New England Journal of Medicine analysis, 38 second-line patients with RAS G12, G13 or Q61 mutations had median progression-free survival of 8.1 months and median overall survival of 15.6 months. The subsequent 500-patient Phase 3 trial then confirmed that the drug really was outperforming standard treatment.

That progression from small early cohorts to a large randomized trial is why we can be much more confident today than when the first spectacular response data appeared.

Q4Are Revolution Medicines patients actually seeing pancreatic tumors disappear?

Daraxonrasib can make pancreatic tumors shrink dramatically, and a few patients have had complete responses, but tumor disappearance remains rare.

The current Phase 3 evidence shows that around three in ten patients had a confirmed objective response. That is a major improvement over chemotherapy, though it still means most patients did not reach the threshold for a partial or complete response.

The earlier first-line studies give us a closer look at very deep responses. In a roughly 40-patient cohort receiving first-line daraxonrasib alone, investigators reported one complete response. Another roughly 40-patient cohort combining daraxonrasib with gemcitabine and nab-paclitaxel also produced one complete response.

A complete response means investigators can no longer detect measurable cancer using the tests and scans used in the trial. It does not guarantee that every cancer cell has disappeared.

That distinction is especially important in pancreatic cancer. Microscopic disease can remain after scans become clear and even after surgeons remove every visible part of a tumor. We would need years of follow-up showing that a meaningful share of these complete responders remain cancer-free before treating complete response as evidence of cure.

Q5How long does daraxonrasib keep pancreatic cancer under control?

Daraxonrasib is currently extending pancreatic cancer control by months rather than keeping most patients disease-free for years.

As seen above, median progression-free survival in the pivotal trial was 7.2 months. By definition, half of the daraxonrasib group had experienced progression or death by around that point.

The earlier Phase 1/2 trial gives us a little more information about durability among patients who actually responded. The New England Journal of Medicine reported a median response duration of 8.2 months in the relevant second-line groups.

Those are good results in metastatic pancreatic cancer, but they also tell us where the drug stands today. We are seeing substantially longer control, sometimes deep control, followed by progression in many patients.

A true metastatic cure signal would eventually produce a different survival pattern: a meaningful group of patients staying cancer-free for several years, ideally after stopping treatment. Daraxonrasib is currently taken once daily until the cancer progresses or side effects make continued treatment impossible. We do not yet have a large long-term treatment-free survivor population.

Q6Can daraxonrasib work for most pancreatic cancer patients?

Daraxonrasib can potentially reach a much larger share of pancreatic cancers than earlier mutation-specific KRAS drugs because it targets several forms of active RAS at once.

More than 90% of pancreatic ductal adenocarcinomas are driven by RAS mutations, overwhelmingly in KRAS. The biggest groups include KRAS G12D, G12V and G12R.

That distribution created an awkward problem for the first wave of KRAS drugs. KRAS G12C was the mutation that initially proved most druggable, but G12C appears in only around 1% to 2% of pancreatic cancers. A spectacular G12C drug therefore leaves almost the entire pancreatic cancer population untouched.

Daraxonrasib was designed differently. Revolution Medicines built it as a multi-selective RAS(ON) inhibitor that can attack several active mutant forms of KRAS, NRAS and HRAS, while also interacting with active wild-type RAS.

That breadth is now visible in the FDA label. The metastatic pancreatic cancer approval does not require one specific KRAS mutation, which gives daraxonrasib a much wider practical reach than a G12C-only treatment.

RAS groups and daraxonrasib relevance in pancreatic cancer

Q7Why can Revolution Medicines target KRAS when older drugs struggled?

Revolution Medicines found a way to attack active RAS across several mutations, which is a much better fit for pancreatic cancer than targeting one rare KRAS variant at a time.

RAS proteins act like molecular switches. Cancer-causing mutations can keep the switch abnormally active, continuously sending growth signals through the cell.

Daraxonrasib binds through a mechanism Revolution Medicines calls a tri-complex. The drug uses the intracellular protein cyclophilin A to form a complex with active, GTP-bound RAS. That complex blocks RAS from efficiently passing its growth signal downstream.

The more interesting part is the state of RAS being targeted. Daraxonrasib goes after the active "ON" form of the protein. Earlier KRAS inhibitors often focused on one mutant form and, in some cases, the inactive "OFF" state.

Pancreatic cancer is unusually dependent on RAS while also being split across several KRAS variants. A multi-selective active-state inhibitor fits the biology of the disease particularly well.

We should still avoid the old "undruggable KRAS has finally been solved" line. KRAS drugs already exist, and resistance to daraxonrasib is now documented. Revolution Medicines has made RAS much more druggable in pancreatic cancer. It has not made the biology simple.

Q8Is daraxonrasib actually easier to tolerate than pancreatic cancer chemotherapy?

Daraxonrasib currently gives patients a better survival outcome with a more manageable treatment burden than the chemotherapy it beat in RASolute 302.

Longer survival becomes less impressive if it comes from a treatment patients can barely tolerate. Daraxonrasib is an oral tablet taken once daily, while standard pancreatic cancer chemotherapy involves intravenous treatment and carries substantial cumulative toxicity.

The FDA lists important daraxonrasib risks, including skin and soft-tissue toxicity, mouth inflammation, diarrhea, gastrointestinal perforation and interstitial lung disease. So we should not describe it as an easy drug.

Still, the clinical comparison favored daraxonrasib. Earlier presentations from RASolute 302 reported fewer high-grade treatment-related adverse events and far fewer discontinuations caused by treatment toxicity than in the chemotherapy group.

Patient-reported outcomes pointed in the same direction. Pain and overall quality of life deteriorated later in patients receiving daraxonrasib.

For metastatic pancreatic cancer, getting substantially longer survival without demanding a harsher treatment experience is a big part of why oncologists are treating this drug seriously.

Q9Is daraxonrasib now the standard second-line pancreatic cancer treatment?

Daraxonrasib has a strong case to become the default second-line option for many eligible metastatic pancreatic cancer patients now that the FDA has approved it.

The comparison against existing treatment is unusually straightforward. RASolute 302 directly randomized patients between daraxonrasib and physician-selected standard chemotherapy, and daraxonrasib won on overall survival, progression-free survival and response rate.

The trial also enrolled 500 patients, so we are no longer extrapolating from a boutique molecular cohort. The FDA reviewed the randomized data and approved the treatment for metastatic pancreatic adenocarcinoma after prior systemic therapy without requiring one narrow KRAS subtype.

Real-world adoption will still depend on access, physician experience, contraindications and how treatment guidelines incorporate the approval. Some patients will also have clinical reasons to receive another regimen.

But the scientific argument has changed. Daraxonrasib no longer needs to prove that it deserves a place in second-line therapy. Competitors and alternative regimens now need to explain why an eligible patient should receive something else.

Q10Could daraxonrasib work even better before chemotherapy?

Daraxonrasib could become even more important in first-line pancreatic cancer, but the impressive early response rates still need to survive a large randomized trial.

Two small first-line datasets presented at AACR produced results worth watching. Among 38 evaluable patients with RAS-mutant metastatic pancreatic cancer receiving daraxonrasib alone, 47% had an objective response and 92% achieved disease control.

A separate 40-patient study combined daraxonrasib with gemcitabine and nab-paclitaxel. The response rate reached 58% and the disease-control rate reached 90%. At six months, an estimated 84% of patients remained progression-free and 90% were alive.

Those response rates compare well with modern chemotherapy. NAPOLI 3 reported a 41.8% objective response rate with NALIRIFOX and 36.2% with gemcitabine plus nab-paclitaxel.

The uncertainty comes from sample size and trial design. Forty patients in an early study can look much better than hundreds of patients in a randomized Phase 3 trial simply because the populations differ.

Revolution Medicines is now testing the question properly. RASolute 303 is recruiting around 900 previously untreated metastatic pancreatic cancer patients and compares daraxonrasib alone, daraxonrasib plus gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alone. Until those survival data arrive, we would treat the first-line numbers as genuinely exciting rather than settled.

First-line daraxonrasib response rates versus modern chemotherapy benchmarks

Q11Is Revolution Medicines testing daraxonrasib where pancreatic cancer can actually be cured?

Revolution Medicines is now testing daraxonrasib after pancreatic cancer surgery, and this is the part of the program that could eventually tell us whether the drug helps cure more patients.

RASolute 304 is a recruiting Phase 3 trial of about 500 patients whose pancreatic ductal adenocarcinoma has been surgically removed. They must also have completed chemotherapy around the time of surgery. The study then compares daraxonrasib with standard observation.

The main question is whether daraxonrasib can keep the cancer from returning.

That is much closer to a cure question than the metastatic trials. After curative-intent surgery, doctors may see no remaining cancer at all, but microscopic cells can survive and later cause recurrence. A systemic RAS inhibitor could theoretically kill some of that residual disease.

The benchmark leaves plenty of room for improvement. In the long-term PRODIGE 24 results, patients receiving modified FOLFIRINOX after surgery had median disease-free survival of 21.4 months. Only 26.1% were disease-free at five years, although 43.2% were still alive.

RASolute 304 currently has no efficacy results, so we cannot credit daraxonrasib with preventing recurrence yet. But if Revolution Medicines eventually raises that long-term disease-free survival rate by a meaningful amount, the conversation around "cure" becomes much more serious.

Q12Is pancreatic cancer already becoming resistant to daraxonrasib?

Yes. We already have direct evidence that pancreatic cancers can evolve around daraxonrasib, which sharply limits any cure claim today.

A recent Nature Medicine study examined paired blood samples from 44 pancreatic cancer patients treated with daraxonrasib who later reached the end of treatment. Researchers found newly acquired alterations in the RAS signaling pathway in 26 patients, or 59% of the group.

The most common escape route was amplification of mutant KRAS itself, found in 16 of the 44 patients. Researchers also saw new alterations involving MAPK, receptor tyrosine kinase and PI3K signaling.

The pattern is revealing. Daraxonrasib puts enough pressure on pancreatic tumors that some cancers evolve ways to reactivate the same growth system the drug is suppressing.

Researchers are already using those findings to design combinations. In preclinical models, pairing daraxonrasib with drugs targeting DNA-damage pathways, receptor tyrosine kinases or Revolution Medicines' G12D-selective drug zoldonrasib helped prevent some resistance mechanisms.

For now, resistance is not a theoretical future problem. We can already see it happening in patients.

Q13So, has Revolution Medicines cured pancreatic cancer?

No. Revolution Medicines has not cured pancreatic cancer, although daraxonrasib has now crossed the much more credible threshold of being a major treatment breakthrough.

The current evidence is strong enough for us to be assertive about what Revolution Medicines has achieved. Daraxonrasib has beaten standard chemotherapy in a 500-patient randomized Phase 3 trial, roughly doubled median overall survival and progression-free survival, produced far more tumor responses, and earned FDA approval for previously treated metastatic pancreatic adenocarcinoma.

The cure evidence is missing. Most metastatic patients eventually progress, complete responses remain uncommon, daraxonrasib is given continuously rather than as a finite curative treatment, and researchers can already identify genetic routes through which pancreatic tumors develop resistance.

What makes the story especially interesting today is how quickly the question could evolve. Revolution Medicines is already running a 900-patient first-line Phase 3 trial and a separate 500-patient Phase 3 trial after potentially curative surgery. The latter is the one we would watch most closely for a true cure signal because it can show whether daraxonrasib prevents cancers from ever coming back.

Our judgment today is clear: Revolution Medicines has dramatically improved how some pancreatic cancers can be treated, but saying it has cured pancreatic cancer goes well beyond the evidence. The company would need durable multi-year remissions, preferably treatment-free, or a meaningful rise in long-term disease-free survival after surgery before that claim becomes defensible.